Table 3.
Autoantibodies in Xenobiotic-Induced Autoimmunity and Autoimmune Disease.
Xenobiotic | Autoimmune Diseases or Autoimmunitya | Idiopathicb | Xenobiotic Humanc | Xenobiotic Experimentalc | Selected References |
---|---|---|---|---|---|
Confident | |||||
Silica | SLE, SSc, RA |
ANA DNA, Sm, RNP, SS-A/Ro, SS-B/La Centromere, DNA topoisomerase 1 RF ACPAd |
ANA DNA SS-A/Ro SS-B/La Centromere, DNA topoisomerase 1 ACPA |
ANA Sm RNP dsDNA RF |
(21, 25, 30, 111,112,113) (25, 29) (123) |
Smoking | Seropositive RA | RF ACPA |
ACPA | (19) | |
Solvents | SSc | Scl-70 | Scl-70 |
MDA HNE ssDNA dsDNA |
(126) (95) |
Insufficient evidence | |||||
Mercury | autoantibodies, cytokines, nephrotic syndrome | NA | ANA | ANA Fibrillarin Chromatin |
(3) |
Asbestos | autoantibodies, atypical rheumatological symptoms | NA | ANA dsDNA RNP SS-A/Ro52 Scl-70 Mesothelial cell |
ANA dsDNA SS/A-Ro52 Mesothelial cell |
(127) |
Note: This table is not a comprehensive listing of all autoantibodies found in a particular idiopathic autoimmune disease. Rather it is a comparison of autoantibody responses found with a specific xenobiotic exposure and whether the same response has been identified in idiopathic disease.
Exposures leading to autoimmunity without clinical disease are mercury and asbestos.
Idiopathic disease means no known association with an environmental exposure.
Antibodies in humans or experimental animal models following exposure.
In italics, antibodies against post-translational protein modification.
Abbreviations: NA, not applicable.